Sugi Predict

Sugi Predict / Compounds / SCHEMBL4457946

SCHEMBL4457946

SCHEMBL4457946

CC(C)Oc1c(-c2ccccc2)cc(Cl)c2cccnc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 3/20 0.47
▸ CCR1 P32246 1/20 0.47
▸ CCR8 P51685 1/20 0.47
▸ HIF1A Q16665 2/20 0.46
▸ KDM4E B2RXH2 3/20 0.43
▸ ALDH1A1 P00352 7/20 0.42
▸ MAPT P10636 5/20 0.42
▸ LMNA P02545 4/20 0.42
▸ ALOX12 P18054 4/20 0.42
▸ HTT P42858 4/20 0.42
▸ SMN1; SMN2 Q16637 4/20 0.42
▸ HSP90AA1 P07900 4/20 0.42
▸ MMP14 P50281 3/20 0.42
▸ MEN1 O00255 3/20 0.42
▸ CYP3A4 P08684 3/20 0.42
▸ KMT2A Q03164 3/20 0.42
▸ TP53 P04637 2/20 0.42
▸ ALOX15 P16050 2/20 0.42
▸ SLC6A2 P23975 2/20 0.42
▸ OPRK1 P41145 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4455362 0.90 L3MBTL1 (0.53) L3MBTL1CCR1CCR8HIF1AKDM4E
SCHEMBL16407673 0.90 COMT (0.45) L3MBTL1CCR1CCR8HIF1AKDM4E
SCHEMBL13625110 0.89 L3MBTL1 (0.43) L3MBTL1CCR1CCR8HIF1AKDM4E
SCHEMBL4455356 0.88 CKS1B (0.42) L3MBTL1CCR1CCR8HIF1AALDH1A1
SCHEMBL16407667 0.88 L3MBTL1 (0.43) L3MBTL1CCR1CCR8HIF1AKDM4E
SCHEMBL13625108 0.88 KMT2A (0.44) L3MBTL1CCR1CCR8HIF1AKDM4E
SCHEMBL4036442 0.87 PIK3CD (0.49) L3MBTL1CCR1CCR8HIF1AKDM4E
SCHEMBL13625135 0.87 PIK3CD (0.44) L3MBTL1CCR1CCR8HIF1AKDM4E
SCHEMBL4036628 0.87 L3MBTL1 (0.42) L3MBTL1CCR1CCR8HIF1AKDM4E
SCHEMBL13625117 0.86 L3MBTL1 (0.43) L3MBTL1CCR1CCR8HIF1AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression SIERRA SCIENCES, INC. (US) 2023-07-18 — — US disclosed
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression SIERRA SCIENCES, INC. (US) 2023-07-18 — — US disclosed
US-9302993-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2016-04-05 — — US disclosed
US-9302993-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2016-04-05 — — US disclosed
US-20150335635-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2015-11-26 — — US disclosed
US-20150335635-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2015-11-26 — — US disclosed
US-9169211-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2015-10-27 — — US disclosed
US-9169211-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2015-10-27 — — US disclosed
US-20150094334-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2015-04-02 — — US disclosed
US-20150094334-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2015-04-02 — — US disclosed
US-7619091-B2 Treating nervous system disorders such as mild cognitive impairment, Alzheimer's disease or dementia associated with Down syndrome; e.g. use of 5,7-dichloro-8-hydroxy-2-(2-pyridyl)-quinoline (PBT 1052) PRANA BIOTECHNOLOGY LIMITED (AU) 2009-11-17 — — US disclosed
US-7619091-B2 Treating nervous system disorders such as mild cognitive impairment, Alzheimer's disease or dementia associated with Down syndrome; e.g. use of 5,7-dichloro-8-hydroxy-2-(2-pyridyl)-quinoline (PBT 1052) PRANA BIOTECHNOLOGY LIMITED (AU) 2009-11-17 — — US disclosed
US-20080161353-A1 8-Hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2008-07-03 — — US disclosed
US-20080161353-A1 8-Hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2008-07-03 — — US disclosed
US-20080161353-A1 8-Hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2008-07-03 — — US disclosed
EP-1539700-A4 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LTD (AU) 2006-06-28 — — EP disclosed
US-20060089380-A1 8-Hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LTD. (AU) 2006-04-27 — — US disclosed
CN-1681791-A 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LTD (AU) 2005-10-12 — — CN disclosed
EP-1539700-A1 8-HYDROXY QUINOLINE DERIVATIVES Prana Biotechnology Ltd (AU) 2005-06-15 — — EP disclosed
WO-2004007461-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2004-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150335635-A1 8-HYDROXY QUINOLINE DERIVATIVES PARK7, COQ8A, NLN L3MBTL1 3725/4885CCR1 3231/4885CCR8 1054/4885
US-20080161353-A1 8-Hydroxy quinoline derivatives PARK7, COQ8A, NLN L3MBTL1 3725/4885CCR1 3231/4885CCR8 1054/4885
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression TERT, TERF2, RNGTT L3MBTL1 1268/4885CCR1 4654/4885CCR8 2028/4885
US-20060089380-A1 8-Hydroxy quinoline derivatives PARK7, HTT, SNCA L3MBTL1 4048/4885CCR1 4614/4885CCR8 2677/4885
US-20150094334-A1 8-HYDROXY QUINOLINE DERIVATIVES PARK7, COQ8A, NLN L3MBTL1 3725/4885CCR1 3231/4885CCR8 1054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.